As of August 29, 2026, ProQR Therapeutics's top three insider holders are Boer Daniel Anton De (Chief Executive Officer, 500.00K shares), Bart Filius (Director, 300.00K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Boer Daniel Anton De | Chief Executive Officer | 500,000 | 0 | 500,000 | 62.5% | 03 Aug, 2026 |
| 2 | Bart Filius | Director | 300,000 | 0 | 300,000 | 37.5% | 21 Jul, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 31 Jul, 2026 | Boer Daniel Anton De | Chief Executive Officer | Acquired P | 200,000 | $1.77 | $353.96K | 500,000 | Direct |
| 17 Jul, 2026 | Bart Filius | Director | Acquired P | 150,000 | $1.72 | $257.93K | 300,000 | Direct |
| 09 Jul, 2026 | Boer Daniel Anton De | Chief Executive Officer | Acquired P | 150,000 | $1.74 | $261.00K | 300,000 | Direct |
| 07 Jul, 2026 | Boer Daniel Anton De | Chief Executive Officer | Acquired P | 150,000 | $1.59 | $238.50K | 150,000 | Direct |
| 02 Jun, 2026 | Gylvin Lykke Hinsch | Director | Acquired A | 14,595 | $0.00 | $0 | 14,595 | Direct |
| 26 Jun, 2026 | Bart Filius | Director | Acquired P | 150,000 | $1.54 | $231.00K | 150,000 | Direct |
| 02 Jun, 2026 | Gylvin Lykke Hinsch | Director | Acquired A | 14,495 | $0.00 | $0 | 14,495 | Direct |